Research map: Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies

Back to the article

Papers in this map

  1. International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy · International Association of Diabetes and Pregnancy Study Groups Consensus Panel · 2010 · 5499 citations · Cited by this paper
  2. Balance Rehabilitation in Patients with Traumatic Brain Injury: A Scoping Review · 2026 · Related
  3. Once-Weekly Semaglutide in Adults with Overweight or Obesity · John P.H. Wilding · 2021 · 5054 citations · Cited by this paper
  4. Short-Term Association of Add-On Gosha-Jinki-Gan with Sleep and Nocturia Outcomes in Patients with Persistent Nocturia Despite Desmopressin: A Real-World Study · 2026 · Related
  5. Inflammatory Mechanisms in Obesity · Margaret F. Gregor · 2011 · 3751 citations · Cited by this paper
  6. Angular and Rotational Lower Limb Alignment Variations in Children: Practical Guidance for Paediatricians · 2026 · Related
  7. Tirzepatide Once Weekly for the Treatment of Obesity · Ania M. Jastreboff · 2022 · 3661 citations · Cited by this paper
  8. Update on antiobesity pharmacotherapy in adults: Current and emerging options · 2026 · Related
  9. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management · Xavier Pi-Sunyer · 2015 · 2707 citations · Cited by this paper
  10. Blood Transfusion and ABO Blood Groups in Sickle Cell Disease · 2026 · Related
  11. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes · Juan P. Frías · 2021 · 2036 citations · Cited by this paper
  12. The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials · 2025 · Related
  13. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study · Jarl Torgerson · 2004 · 1920 citations · Cited by this paper
  14. Serum YKL-40 in Non-ST-Segment Elevation Acute Coronary Syndrome: A Prospective Exploratory Emergency Department Study · 2026 · Related
  15. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child · Patrick M. Catalano · 2017 · 1359 citations · Cited by this paper
  16. Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications · 2025 · Related
  17. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025 · Nuha A. ElSayed · 2024 · 1318 citations · Cited by this paper
  18. From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management? · 2025 · Related
  19. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide · Jesper F. Lau · 2015 · 1093 citations · Cited by this paper
  20. Beyond metabolism: sexual dysfunction and weight-loss drugs · 2025 · Related
  21. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial · Frank L. Greenway · 2010 · 1038 citations · Cited by this paper
  22. Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome · Richard S. Legro · 2007 · 1029 citations · Cited by this paper
  23. The Discovery and Development of Liraglutide and Semaglutide · Lotte Bjerre Knudsen · 2019 · 966 citations · Cited by this paper
  24. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome · Helena Jane Teede · 2023 · 880 citations · Cited by this paper
  25. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events · Rohan Khera · 2016 · 875 citations · Cited by this paper
  26. Obesity and female infertility: potential mediators of obesity's impact · Darcy E. Broughton · 2017 · 873 citations · Cited by this paper
  27. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity · Louis J. Aronne · 2023 · 825 citations · Cited by this paper
  28. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II) · Caroline M. Apovian · 2013 · 723 citations · Cited by this paper
  29. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity · John Edward Blundell · 2017 · 688 citations · Cited by this paper
  30. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls · Selma Feldman Witchel · 2019 · 657 citations · Cited by this paper
  31. Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial · Thomas A. Wadden · 2010 · 559 citations · Cited by this paper
  32. Obesity and reproductive disorders in women · Renato Pasquali · 2003 · 544 citations · Cited by this paper
  33. Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes · Priscilla A. Hollander · 2013 · 501 citations · Cited by this paper
  34. The menace of obesity to depression and anxiety prevalence · Stephanie Fulton · 2021 · 449 citations · Cited by this paper
  35. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review · Stefano Palomba · 2008 · 435 citations · Cited by this paper
  36. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial · Thomas A. Wadden · 2023 · 428 citations · Cited by this paper
  37. Current pharmacotherapy for obesity · Gitanjali Srivastava · 2017 · 421 citations · Cited by this paper
  38. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies · Thomas M. Barber · 2019 · 419 citations · Cited by this paper
  39. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial · Filip Krag Knop · 2023 · 417 citations · Cited by this paper

Source: OpenAlex (CC0)